Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

NCT06790303 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Due to low enrolment of participants

Conditions

Neoplasms

Interventions

DRUG: Feladilimab
DRUG: Ipilimumab

Sponsor

GlaxoSmithKline